Leveraging A Global Drug Development Program To Ensure Clinical Trial Success

At the onset of a new era in the drug development industry, biotechnology companies are looking for ways to effectively utilize capital and increase asset valuation in an unstable market. Many companies with early-stage development programs are struggling to thrive in the current environment due to reduced funding opportunities that place a greater burden on clinical development programs to succeed. Expanding globally can help save crucial resources and produce high-quality clinical data. However, a globalized approach takes careful planning to ensure regulatory approval.

Experts recommend early globalization of development assets to leverage unique regional advantages that help accelerate data to its inflection point. For example, a company may opt for indication expansion into a country with high disease prevalence, which can generate global value and conserve resources. Delays in getting into Phase 1 units in the U.S. and Europe have made Asia-Pacific (APAC) countries increasingly attractive destinations for early-phase trials where high-integrity, high-quality Phase 1 opportunities exist. Download for greater insight into how to build a global program, including how to identify global partners with proven track records that can help your therapy reach patients faster.